Daniel Tanner is the Chief Commercial Officer for Cerba Research and responsible for the organization’s commercial success by developing strategic business plans to drive sales and revenue with a focus on long-term value creation, including M&A and new service development. Daniel leads the global sales organizations, sales operations, and global strategic account teams for Cerba Research’s full suite of services and solutions for biopharmaceutical, medical device and diagnostics customers. He has nearly 20 years of drug development and clinical trial-related sales, strategy and leadership.
Prior to Cerba Research, Daniel was employed at several leading CROs, including Parexel and ICON, in strategic and business development roles covering the full spectrum of clinical trial services and technology.
Daniel holds a degree in Biochemistry from the University of Warwick and an Executive MBA from the Imperial College Business School.
Professional Experience
- Chief Commercial Officer (CCO), Cerba Research (2018 – Present)
- Vice President, eHealth – Enterprise Accounts, Bioclinica (2017 – 2018)
- Senior Director Business Development, PAREXEL (2013 – 2016)
- Director Sales Strategic Development, ICON plc (2009 – 2013)
- Business Development Executive, Kendle International (2006 – 2009)
- CRA, InVentiv Health Clinical (2004 – 2006)